We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00977288
First Posted: September 15, 2009
Last Update Posted: May 6, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
  Purpose
This study will investigate the effect of MK0859 when administered alone and when in combination with atorvastatin in lowering Low Density Lipoprotein -Cholesterol (LDL-C) in Japanese patients with dyslipidemia.

Condition Intervention Phase
Dyslipidemia Drug: anacetrapib Drug: Comparator: atorvastatin Drug: Comparator: Placebo Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIb, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Dose-Ranging Study to Assess the Efficacy and Safety of MK0859 in Japanese Patients With Dyslipidemia

Further study details as provided by Merck Sharp & Dohme Corp.:

Primary Outcome Measures:
  • The percent change from baseline in Low Density Lipoprotein -Cholesterol at week 8 [ Time Frame: 8 weeks ]

Secondary Outcome Measures:
  • The percent change from baseline in High Density Lipoprotein-Cholesterol and safety (hepatitis related AEs, myalgia, rhabdomyolysis, blood pressure, laboratory tests: ALT, AST, CK, Na, Cl, bicarbonate, and K), at week 8 [ Time Frame: 8 weeks ]

Enrollment: 408
Study Start Date: September 2009
Study Completion Date: April 2014
Primary Completion Date: March 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
MK0859 10 mg + placebo
Drug: anacetrapib
10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
Other Name: MK0859
Drug: Comparator: Placebo
Placebo tablet, once daily for 8 weeks
Experimental: 2
MK0859 40 mg + placebo
Drug: anacetrapib
10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
Other Name: MK0859
Drug: Comparator: Placebo
Placebo tablet, once daily for 8 weeks
Experimental: 3
MK0859 100 mg + placebo
Drug: anacetrapib
10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
Other Name: MK0859
Drug: Comparator: Placebo
Placebo tablet, once daily for 8 weeks
Experimental: 4
MK0859 300 mg + placebo
Drug: anacetrapib
10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
Other Name: MK0859
Drug: Comparator: Placebo
Placebo tablet, once daily for 8 weeks
Experimental: 5
MK0859 10 mg + atorvastatin 10mg
Drug: anacetrapib
10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
Other Name: MK0859
Drug: Comparator: atorvastatin
atorvastatin tablet, 10mg, once daily for 8 weeks
Experimental: 6
MK0859 40 mg + atorvastatin 10mg
Drug: anacetrapib
10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
Other Name: MK0859
Drug: Comparator: atorvastatin
atorvastatin tablet, 10mg, once daily for 8 weeks
Experimental: 7
MK0859 100 mg + atorvastatin 10mg
Drug: anacetrapib
10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
Other Name: MK0859
Drug: Comparator: atorvastatin
atorvastatin tablet, 10mg, once daily for 8 weeks
Experimental: 8
MK0859 300 mg + atorvastatin 10mg
Drug: anacetrapib
10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
Other Name: MK0859
Drug: Comparator: atorvastatin
atorvastatin tablet, 10mg, once daily for 8 weeks
Placebo Comparator: 9
Placebo + atorvastatin 10mg
Drug: Comparator: atorvastatin
atorvastatin tablet, 10mg, once daily for 8 weeks
Drug: Comparator: Placebo
Placebo tablet, once daily for 8 weeks
Placebo Comparator: 10
Placebo
Drug: Comparator: Placebo
Placebo tablet, once daily for 8 weeks

Detailed Description:

This is the dose ranging study to evaluate efficacy and safety of MK-0859 in Japanese patients.

Eligible patients were assigned to 1 of 10 treatment groups (including treatment groups with or without administrative atorvastatin) for an 8-week treatment period which was followed by a 8-week reversibility period.

As an additional follow-up, the pregnancy information from women of childbearing potential who were treated with MK-0859 in this study will be collected retrospectively for a period of 4 years after the last dose of MK-0859.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patient is male or female and between the ages of 20 and 75 years diagnosed with dyslipidemia

Exclusion Criteria:

  • Patients has Coronary Heart Disease (CHD) or CHD-equivalent disease (except diabetes)
  • Patients has uncontrolled diabetes
  • Patient is currently participating or has participated in a study with an investigational compound within the last 3 months
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00977288


Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Investigators
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Publications:
Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00977288     History of Changes
Other Study ID Numbers: 0859-029
2009_662
First Submitted: September 14, 2009
First Posted: September 15, 2009
Last Update Posted: May 6, 2015
Last Verified: May 2015

Additional relevant MeSH terms:
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Atorvastatin Calcium
Anacetrapib
Oxazolidinones
Anticholesteremic Agents
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Enzyme Inhibitors
Anti-Infective Agents
Protein Synthesis Inhibitors


To Top